| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Arie Mayer is Director at ORMP. Arie Mayer's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $694K at current prices.
Our model assigns Arie Mayer a strong insider score of 76/100, based on 3 past trades. Over a 12-month horizon, all 3 of those trades were profitable, with an average 12-month return of +42.3%.
Net of sales, the ORMP filings show accumulation of 5,809 shares.
Arie Mayer has 9 Form 4 filings on record from January 2020 to December 2025, all as Director at Oramed Pharmaceuticals (ORMP), 2020–2025.
The 14 reported transactions were 9 stock awards, 2 open-market purchases, 2 option or other derivative awards and 1 open-market sale.
Counted by filing, the open-market trades come to 1 purchase worth about $20K and 1 sale worth about $77K.
The only open-market purchase was 8,809 shares of ORMP at an average $2.22 on April 4, 2023, about $20K. Twelve months later ORMP was up 27%.
The only open-market sale was 3,000 shares of ORMP at an average $25.60 on November 1, 2021, about $77K. Twelve months later ORMP was down 73%.